Literature DB >> 23112332

Maturation-dependent HIV-1 surface protein redistribution revealed by fluorescence nanoscopy.

Jakub Chojnacki1, Thorsten Staudt, Bärbel Glass, Pit Bingen, Johann Engelhardt, Maria Anders, Jale Schneider, Barbara Müller, Stefan W Hell, Hans-Georg Kräusslich.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) buds from the cell as an immature particle requiring subsequent proteolysis of the main structural polyprotein Gag for morphological maturation and infectivity. Visualization of the viral envelope (Env) glycoprotein distribution on the surface of individual HIV-1 particles with stimulated emission depletion (STED) superresolution fluorescence microscopy revealed maturation-induced clustering of Env proteins that depended on the Gag-interacting Env tail. Correlation of Env surface clustering with the viral entry efficiency revealed coupling between the viral interior and exterior: Rearrangements of the inner protein lattice facilitated the alteration of the virus surface in preparation for productive entry. We propose that Gag proteolysis-dependent clustering of the sparse Env trimers on the viral surface may be an essential aspect of HIV-1 maturation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23112332     DOI: 10.1126/science.1226359

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  131 in total

Review 1.  Superresolution imaging of viral protein trafficking.

Authors:  Anamaris M Colberg-Poley; George H Patterson; Kyle Salka; Shivaprasad Bhuvanendran; David Yang; Jyoti K Jaiswal
Journal:  Med Microbiol Immunol       Date:  2015-02-28       Impact factor: 3.402

Review 2.  Recent trends in HIV-1 drug resistance.

Authors:  Janet D Siliciano; Robert F Siliciano
Journal:  Curr Opin Virol       Date:  2013-09-07       Impact factor: 7.090

3.  Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance.

Authors:  S Alireza Rabi; Gregory M Laird; Christine M Durand; Sarah Laskey; Liang Shan; Justin R Bailey; Stanley Chioma; Richard D Moore; Robert F Siliciano
Journal:  J Clin Invest       Date:  2013-08-27       Impact factor: 14.808

4.  Ezrin is a component of the HIV-1 virological presynapse and contributes to the inhibition of cell-cell fusion.

Authors:  Nathan H Roy; Marie Lambelé; Jany Chan; Menelaos Symeonides; Markus Thali
Journal:  J Virol       Date:  2014-04-23       Impact factor: 5.103

5.  Distinct requirements for HIV-cell fusion and HIV-mediated cell-cell fusion.

Authors:  Naoyuki Kondo; Mariana Marin; Jeong Hwa Kim; Tanay M Desai; Gregory B Melikyan
Journal:  J Biol Chem       Date:  2015-01-14       Impact factor: 5.157

6.  Nanomechanical mapping of first binding steps of a virus to animal cells.

Authors:  David Alsteens; Richard Newton; Rajib Schubert; David Martinez-Martin; Martin Delguste; Botond Roska; Daniel J Müller
Journal:  Nat Nanotechnol       Date:  2016-10-31       Impact factor: 39.213

7.  Reaction-diffusion basis of retroviral infectivity.

Authors:  S Kashif Sadiq
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2016-11-13       Impact factor: 4.226

Review 8.  Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity.

Authors:  Laura A VanBlargan; Leslie Goo; Theodore C Pierson
Journal:  Microbiol Mol Biol Rev       Date:  2016-10-26       Impact factor: 11.056

9.  The Myxobacterial Metabolite Soraphen A Inhibits HIV-1 by Reducing Virus Production and Altering Virion Composition.

Authors:  Eric Fleta-Soriano; Katarína Smutná; Javier P Martínez; Cristina Lorca Oró; S Kashif Sadiq; Gilles Mirambeau; Carmen Lopez-Iglesias; Marta Bosch; Albert Pol; Mark Brönstrup; Juana Diez; Andreas Meyerhans
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

10.  Antigenic properties of the HIV envelope on virions in solution.

Authors:  Krishanu Ray; Meron Mengistu; Lei Yu; George K Lewis; Joseph R Lakowicz; Anthony L DeVico
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.